Drugs / ABX203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02249988 | Dec 2014 → Dec 2016 | chronic hepatitis B virus infection | Abivax S.A. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2016-06-17 | Abivax S.A. | Results Analysis of ongoing ABX203 Phase IIb/III trial in chronic hepatitis B virus infection shows good safety, but primary endpoint of study is unlikely to be reached abivax.com ↗
ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative company developing anti-viral therapies and immunotherapeutics for infectious diseases like HIV/AIDS, chronic hepatitis B (CHB), chikungunya, ebola as well as an adjuvant to enhance the immune response, today announced that a futility analysis on the primary end-point of its ABX203-002 trial, a Phase IIb/III trial of ABX203 in CHB patients, determined that the trial is unlikely to reach its primary endpoint. |
| 2015-12-08 | Abivax S.A. | Regulatory ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B abivax.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABX203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02249988 ↗ |
| Modality | Vaccine | “ABX203, a new chronic hepatitis B therapeutic vaccine” NCT02249988 ↗ |